On 1 September 2026, CNE TECH CORP (00611.HK) announced that its indirect wholly-owned subsidiary Jianhe Financial Leasing entered into a three-year lease agreement (from 1 September 2026 to 31 August 2029) with China Nanshan Development (Group) Incorporation to lease an office property of approximately 1,083.26 square meters in Chiwan Headquarters Building, Nanshan District, Shenzhen, at a monthly rent of RMB 166,063.76, with a right-of-use asset of approximately RMB 5.25 million to be recognized. As China Nanshan is the holding company of Nanshan Holdings, a substantial shareholder of the Company, the lease constitutes a connected transaction with the highest applicable percentage ratio exceeding 0.1% but below 5%, subject to reporting and announcement requirements but exempt from the circular and independent shareholders' approval.
On 1 September 2026, YUEXIU PROPERTY (00123.HK) announced that its indirect non-wholly-owned subsidiary Hangzhou Yile entered into a cooperation agreement with Hangzhou Binjiang to increase the target company's registered capital from RMB 50 million to RMB 900 million, with Hangzhou Yile contributing RMB 459 million and Hangzhou Binjiang RMB 391 million, and the parties holding 51% and 49% of the project company respectively upon completion, to jointly develop a residential plot in Gongshu District, Hangzhou with a total land premium of RMB 1.81 billion. The transaction constitutes a connected transaction exempt from the circular and independent shareholders' approval, and the project company's results will be consolidated upon completion.
On 1 September 2026, JIAHUA STORES H (00602.HK) announced that its wholly-owned subsidiary Shenzhen Baijiahua will dispose of the leasehold improvements and equipment of two supermarkets to two lessees for aggregate sublease transfer fees of RMB 14 million, with an expected disposal gain of approximately RMB 6.1 million and ongoing rental income. As the applicable percentage ratios exceed 25% but are below 75%, the transaction constitutes a major disposal and has been approved in writing by Mr. and Madam Zhuang holding approximately 51.61% of the shares, with a circular expected to be dispatched no later than 21 September 2026.
On 1 September 2026, BOSS ZHIPIN-W (02076.HK) announced that Mr. Chen Xu has ceased to act as President due to the rotation arrangement, remaining an executive Director and resuming the role of Chief Marketing Officer, while Mr. Zhang Tao was appointed rotating President with a term until 31 August 2027, continuing as an executive Director and Chief Technology Officer reporting to founder, Chairman and CEO Zhao Peng.
On 1 September 2026, C STRATEGIC TEC (01725.HK) reported unaudited August 2026 revenue of approximately RMB 52.27 million, down approximately 70.97% year on year (August 2025: approximately RMB 180.07 million). The Group, centered on aerospace technology, operates four segments covering the aerospace industry, precision manufacturing, new energy vessels and biotechnology; the figures are unaudited and may differ from those in periodic financial reports.
On 1 September 2026, NSING TECH (02701.HK) announced a plan to invest RMB 60 million of H-share proceeds in Nanjing UCUN Technology Inc. (UCUN) at a pre-money valuation of RMB 590 million, subscribing for new registered capital representing an 8.3333% stake after the investment, to strengthen its customized NOR Flash external storage MCU capabilities. The investment was approved unanimously by the Board, does not constitute a connected transaction, and does not constitute a major asset restructuring.
On 1 September 2026, SERES (09927.HK) reported August 2026 total production of 26,531 vehicles, down 43.67% year on year, and total sales of 27,684 vehicles, down 39.58%, with NEV sales of 24,244 units, down 43.96% and Seres Automobile sales of 20,652 units, down 49.68%. Cumulative total sales for the first eight months reached 250,943 vehicles, down 14.17% year on year.
On 1 September 2026, CSPC PHARMA (01093.HK) announced that SYS6010, its EGFR-targeting antibody-drug conjugate, has been granted another Breakthrough Therapy designation by the NMPA for recurrent or metastatic head and neck squamous cell carcinoma in patients who failed prior immunotherapy and platinum-based chemotherapy. The product has previously received two Breakthrough Therapy designations, and a pivotal Phase III clinical trial of the product as monotherapy for the indication is underway.
On 1 September 2026, GWMOTOR (02333.HK) reported August 2026 sales of 113,396 vehicles, down 1.87% year on year, with cumulative sales of 805,358 vehicles in the first eight months, up 1.98%. August overseas sales totaled 62,517 units and NEV sales reached 40,700 units, with ORA brand sales more than doubling year on year.
On 1 September 2026, SWIRE PACIFIC A (00019.HK) announced the appointment of J.P. Morgan Securities (Asia Pacific) Limited, Morgan Stanley & Co. International plc and The Hongkong and Shanghai Banking Corporation Limited as joint transaction coordinators for a potential accelerated exchange transaction of the HKD 4.7 billion zero-coupon exchangeable bonds due 2027 issued by its wholly-owned subsidiary Swire Pacific Finance, under which the Company would repurchase bonds and concurrently place Cathay Pacific Airways shares to independent third parties. If 90% or more of the aggregate principal amount of bonds is exchanged, repurchased and cancelled, all outstanding bonds may be redeemed at their principal amount.
NewTimeSpace News: September 01, 2026, SUNEVISION(01686.HK) released its Annual Report for the period ended June 30, 2026, Total Revenue stood at HKD 3.12 billion, increased by 6.09% YoY.
NewTimeSpace News: September 01, 2026, NIO-SW(09866.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 57.67 billion, increased by 85.77% YoY.
On 1 September 2026, CONCORD HC GP (02453.HK) announced that controlling shareholder Shanghai Medstar had its existing pledge of the Company's domestic shares fully released on the same day and repledged 96,137,318 domestic shares, representing approximately 49.96% of its directly held shares, in favor of China Credit Trust Co., Ltd. as security for a loan facility of up to RMB 300 million. The aggregate pledged domestic shares represent approximately 12.27% of the total issued shares of the Company.
On 1 September 2026, CSPC PHARMA (01093.HK) announced that the Phase I clinical trial (SYH2056-001) of SYH2056 tablets for the treatment of major depressive disorder has been officially initiated in China. The product is a small-molecule partial 5-HT2A receptor agonist that demonstrated antidepressant efficacy in animal models with a single dose, and preclinical data indicated low risks of off-target effects, hallucinogenic potential and drug dependence. Participant recruitment and screening are underway.
NewTimeSpace News: September 01, 2026, TST PROPERTIES(00247.HK) released its Annual Report for the period ended June 30, 2026, Total Revenue stood at HKD 9.33 billion, increased by 13.32% YoY.
NewTimeSpace News: September 01, 2026, SINO LAND(00083.HK) released its Annual Report for the period ended June 30, 2026, Total Revenue stood at HKD 9.27 billion, increased by 13.32% YoY.
